Right Time and Place for IL12: Targeted Delivery Stimulates Immune Therapy.

Journal Article (Journal Article)

Systemic IL12 therapy has potent antitumor effects, but clinical delivery of this potent cytokine has been complicated by systemic toxicity. A novel strategy to deliver IL12 to the tumor microenvironment appears promising in a first-in-human study, appearing to stimulate tumor-specific adaptive immune responses with minimal systemic toxicity.See related article by Strauss et al., p. 99.

Full Text

Duke Authors

Cited Authors

  • Lyerly, HK; Osada, T; Hartman, ZC

Published Date

  • January 1, 2019

Published In

Volume / Issue

  • 25 / 1

Start / End Page

  • 9 - 11

PubMed ID

  • 30377197

Electronic International Standard Serial Number (EISSN)

  • 1557-3265

Digital Object Identifier (DOI)

  • 10.1158/1078-0432.CCR-18-2819


  • eng

Conference Location

  • United States